Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Akihiro Yoshimura
Observed names:
A. Yoshimura,
AKIHIRO YOSHIMURA
Institutions:
Kyoto Prefectural University of Medicine,
Kyoto first Red Cross hospital,
Japanese Red Cross Society Kyoto Daini Hospital
Observed institutions:
Kyoto Prefectural University of Medicine,
Kyoto first Red Cross hospital,
University Hospital Kyoto Prefectural University of Medicine,
Aichi Cancer Center,
Japanese Red Cross Society Kyoto Daini Hospital,
Aichi Cancer Center Hospital
show all 6
ORCID:
0000-0002-3753-2110
Observed ORCID:
0000-0002-3753-2110
OpenAlex ID:
A5016463556
Works
106
Awards
1
AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells
2019
·
Hirokazu Taniguchi
, Tadaaki Yamada
, et al.
·
Nature Communications
·
399
ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in EGFR -Mutated Non–Small Cell Lung Cancer
2020
·
Naoko Okura
, Naoya Nishioka
, et al.
·
Clinical Cancer Research
·
127
Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer
2020
·
Rong Wang
, Tadaaki Yamada
, et al.
·
Nature Communications
·
126
PDF
Retrospective efficacy analysis of immune checkpoint inhibitors in patients with EGFR‐mutated non‐small cell lung cancer
2019
·
Tadaaki Yamada
, Soichi Hirai
, et al.
·
Cancer Medicine
·
116
PDF
Association of Sarcopenia with and Efficacy of Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer
2019
·
Naoya Nishioka
, Junji Uchino
, et al.
·
Journal of Clinical Medicine
·
97
PDF
Safety and Usefulness of Cryobiopsy and Stamp Cytology for the Diagnosis of Peripheral Pulmonary Lesions
2019
·
Tatsuya Imabayashi
, Junji Uchino
, et al.
·
Cancers
·
44
PDF
Impact of tumor programmed death ligand-1 expression on osimertinib efficacy in untreated EGFR-mutated advanced non-small cell lung cancer: a prospective observational study
2021
·
Akihiro Yoshimura
, Tadaaki Yamada
, et al.
·
Translational Lung Cancer Research
·
39
PDF
Adaptive resistance to lorlatinib via EGFR signaling in ALK-rearranged lung cancer
2023
·
Yuki Katayama
, Tadaaki Yamada
, et al.
·
npj Precision Oncology
·
37
PDF
Carcinoembryonic antigen and CYFRA 21-1 responses as prognostic factors in advanced non-small cell lung cancer
2019
·
Akihiro Yoshimura
, Junji Uchino
, et al.
·
Translational Lung Cancer Research
·
33
PDF
Retrospective analysis of docetaxel in combination with ramucirumab for previously treated non-small cell lung cancer patients
2019
·
Akihiro Yoshimura
, Tadaaki Yamada
, et al.
·
Translational Lung Cancer Research
·
32
PDF
TTF-1 Expression and Clinical Outcomes of Combined Chemoimmunotherapy in Patients With Advanced Lung Adenocarcinoma: A Prospective Observational Study
2023
·
Yuki Katayama
, Tadaaki Yamada
, et al.
·
JTO Clinical and Research Reports
·
29
High levels of AXL expression in untreated EGFR ‐mutated non‐small cell lung cancer negatively impacts the use of osimertinib
2022
·
Akihiro Yoshimura
, Tadaaki Yamada
, et al.
·
Cancer Science
·
24
PDF
Impact of bowel movement condition on immune checkpoint inhibitor efficacy in patients with advanced non‐small cell lung cancer
2019
·
Yuki Katayama
, Tadaaki Yamada
, et al.
·
Thoracic Cancer
·
24
PDF
Epithelial-mesenchymal transition status is a remarkable biomarker for the combination treatment with avutometinib and defactinib in KRAS-mutated non-small cell lung cancer
2024
·
Akihiro Yoshimura
, Mano Horinaka
, et al.
·
British Journal of Cancer
·
18
PDF
Prospective Observational Study Evaluating the Prognostic Value of the G8 Screening Tool for Extensive-Stage Small Cell Lung Cancer Patients Who Received Programmed Death-Ligand 1 Inhibitor plus Platinum–Etoposide Chemotherapy
2023
·
Kenji Morimoto
, Tadaaki Yamada
, et al.
·
Drugs & Aging
·
15
Pembrolizumab monotherapy for untreated PD-L1-Positive non-small cell lung cancer in the elderly or those with poor performance status: A prospective observational study
2022
·
Shinsuke Shiotsu
, Akihiro Yoshimura
, et al.
·
Frontiers in Oncology
·
15
PDF
Predictive Value of Modified Glasgow Prognostic Score and Persistent Inflammation among Patients with Non-Small Cell Lung Cancer Treated with Durvalumab Consolidation after Chemoradiotherapy: A Multicenter Retrospective Study
2023
·
Keiko Tanimura
, Takayuki Takeda
, et al.
·
Cancers
·
14
PDF
Comparing three different anti-PD-L1 antibodies for immunohistochemical evaluation of small cell lung cancer
2019
·
Akihiro Yoshimura
, Tadaaki Yamada
, et al.
·
Lung Cancer
·
13
Clinical Characteristics of Osimertinib Responder in Non-Small Cell Lung Cancer Patients with EGFR-T790M Mutation
2019
·
Akihiro Yoshimura
, Tadaaki Yamada
, et al.
·
Cancers
·
12
PDF
Pulmonary pleomorphic carcinoma with pseudoprogression during nivolumab therapy and the usefulness of tumor markers: A case report
2018
·
Akihiro Yoshimura
, Chieko Takumi
, et al.
·
Clinical Case Reports
·
12
PDF
Predictive value of p53 and AXL immunostaining for the efficacy of immune checkpoint inhibitor-based therapy after osimertinib treatment in patients with epidermal growth factor-mutant non-small cell lung cancer
2023
·
Kenji Morimoto
, Tadaaki Yamada
, et al.
·
Cancer Immunology Immunotherapy
·
11
PDF
Prognostic impact of pleural effusion in EGFR‐mutant non‐small cell lung cancer patients without brain metastasis
2019
·
Akihiro Yoshimura
, Tadaaki Yamada
, et al.
·
Thoracic Cancer
·
11
PDF
Exploration of clinical Biomarkers for guiding treatment selection between chemotherapy and combination therapy with Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel in EGFR-Mutant NSCLC patients after EGFR-TKI Therapy: The SPIRAL-STEP study
2025
·
Kenji Morimoto
, Tadaaki Yamada
, et al.
·
Lung Cancer
·
10
PDF
Combination Therapy of Avutometinib and MRTX1133 Synergistically Suppresses Cell Growth by Inducing Apoptosis in KRASG12D-Mutated Pancreatic Cancer
2025
·
Ema Toyokuni
, Mano Horinaka
, et al.
·
Molecular Cancer Therapeutics
·
9
Analysis of Tumor Heterogeneity Through AXL Activation in Primary Resistance to EGFR Tyrosine Kinase Inhibitors
2023
·
Ryota Nakamura
, Hiroyuki Fujii
, et al.
·
JTO Clinical and Research Reports
·
9
PDF
Show more works
View as search
Works count:
106
Citation count:
1,360
H-index:
15
I10-index:
23
Year
Topic
Type